Browse > Article

Usefulness of FDG-PET/CT as a Diagnostic Tool for Routine Post Therapy Evaluation in Endometrial Cancer  

Lee, Shin-Jae (Department of Radiology, CHA Bundang Medical center, CHA University)
Jeon, Tae-Joo (Department of Nuclear medicine, CHA Bundang Medical center, CHA University)
Kim, Seung-Jo (Department of Gynecologic Oncology, CHA Bundang Medical center, CHA University)
Kim, Hee-Jin (Department of Radiology, CHA Bundang Medical center, CHA University)
An, Hee-Jung (Department of pathology, CHA Bundang Medical center, CHA University)
Publication Information
Nuclear Medicine and Molecular Imaging / v.43, no.4, 2009 , pp. 301-308 More about this Journal
Abstract
Purpose: The aim of this study was to evaluate the usefulness of FDG-PET/CT as follow up imaging tool in patients with endometrial cancer after therapy. Material and Methods: One hundred one patients with endometrial cancer who underwent FDG PET/CT after the treatment of this disease were included in this study population (25-79 yr old, Mean age 50.6 yr old) and all these patients also performed various laboratory and imaging studies such as serum tumor marker, CT or MRI. The lesions having increased focal FDG uptake were classified into benign, equivocal, and malignant one according to their pattern and activity. Tumor recurrence was confirmed by histopathological results and other clinical and imaging data. Results: Among the 19 patients with 30 malignant or equivocal hot uptakes, 11 of 14 patients supposed to be malignant finding in PET/CT were proved to be tumor recurrence, while one of 5 patients with equivocal lesions were recurred malignancy, Two false negative cases were turned out to be peritoneal carcinomatosis, Estimated sensitivity, specificity and accuracy of PET/CT for diagnosis of recurrence in endometrial carcinoma after treatment were 86 %, 92 % and 91 %, respectively. Positive and negative predictive values in the same issue were 63% and 98%, respectively. Conclusion: FDG-PET/CT is useful for regular work up of endometrial carcinoma after the treatment because of its high negative predictive value as well as high sensitivity and specificity.
Keywords
Endometrial cancer; PET/CT; F-18 FDG;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ryu SY, Kim MH, Choi SC, Choi CW, Lee KH Detection of early recurrence with $^{18}$F-FOO PET in patients with cervical cancer. J Nucl Med 2003;44:347-52   ScienceOn
2 Metser U, Golan O, Levine CD, Even-Sapir E. Tumor lesion detection: when is integrated positron emission tomography/computed tomography more accurate than side-by-side interpretation of positron emission tomography and computed tomography. J Comput Assist Tomogr 2005;29:554-9   DOI   ScienceOn
3 Saga T, Higashi T, Ishimori T, Mameda M, Nakamoto Y, Mukai T, et al. Clinical value of FDG-PET in the follow up of postoperative patients with endometrial cancer. Ann Nucl Med 2003;17:193-203   PUBMED
4 Chao A, Chang TC, Ng KK, Hsueh S, Huang ill, Chou HH, et al. $^{18}$F-FDG PET in the management of endometrial cancer. Eur J Nucl Med Mol Imaging 2006;33:36-44   DOI   ScienceOn
5 Jemal A, Siegel R, Ward E. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30   DOI   ScienceOn
6 Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 1984;17:85-103   DOI   ScienceOn
7 Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol 2000;95:692-6   DOI   ScienceOn
8 Chung HH, Kim SK, Kim TH, Lee S, Kang KW, Kim JY, et al. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine celvical cancer: from diagnosis to prognosis. Gynecol Oncol 2006;103:165-70   DOI   ScienceOn
9 Kim CK, Park BK, Choi JY, Kim BG, Han H. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. J Comput Assist Tomogr 2007;31:868-75   DOI   ScienceOn
10 Shumsky AG, Stuart GC, Brasher PM, Nation JG. Robertson DI, Sangkara S. An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 1994;55:229-33   DOI   ScienceOn
11 Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, et al. The clinical impact of [$^{18}$F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings Eur J Nucl Med Mol Imaging 2008;35:1081-8   DOI   ScienceOn
12 De Leyn P, Stroobants S, De Wever W, Lerut T, Coosemans W, Decker G, et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 2006;24:3333-9   DOI   ScienceOn
13 Cherchi PL, Dessole S, Ruiu GA, Ambrosini G, Farina M, Capobianco G, et al. The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma. Eur J Gynaecol Oncol 1999;20:315-7   PUBMED   ScienceOn
14 Irvin WP, Rice L W, Berkowitz RS. Advances in the management of endometrial adenocarcinoma A review. J Reprod Med 2002;47:173-89   PUBMED   ScienceOn
15 Salvesen HB, Akslen LA, Iversen T, Iversen OE. Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol 1997;104:1302-07   DOI   PUBMED   ScienceOn
16 Jimenez-Bonilla J, Maldonado A, Morales S, Salud A, Zomeno M, Roman J, et al. Clinical impact of $^{18}$F-FDG_PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels. Clin Positron Imaging 2000;3:231-6   DOI   ScienceOn
17 Belhocine T, Debarsy C, Hustinx R, Willems-Foidart J. Usefulness of $^{18}F$-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002;9:1132-9
18 Pelosi E, Messa C, Sironi S, Picchio M, Landoni C, Bettinardi V, et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 2004;31:932-9   DOI   PUBMED   ScienceOn
19 Forstner R, Hricak H, Powell CB, Azizi L, Frankel SB, Stem JL. Ovarian cancer recurrence: value of MR imaging. Radiology 1995;196:1131-40   PUBMED
20 Zimny M, Siggelkow W, Schroder W, Nowak B, Biemann S, Rath W, et al. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001;83:310-5   DOI   ScienceOn
21 Sun SS, Chen TC, Yen RF, Shen YY, Changlai SP, Kao A Value of whole body $^{18}$F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer. Anticancer Res 2000;21:2957-61
22 Annual report of gynecologic cancer registry program in Korea for 2002 (2002.1.1-2002.12.31). Korean J Obstet Gynecol 2004;47:1029-70
23 Reinartz P, Wieres FJ, Schneider W, Schur A, Buell U. Side-byside reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT. Eur J Nucl Med Mol Imaging 2004;31:1456-61   DOI   ScienceOn
24 Eubank WB, Mankoff DA, Vesselle HJ, Eary JF, Schubert EK, Dunnwald LK, et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 2002;22:5-17   DOI   PUBMED   ScienceOn
25 Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-32   DOI   ScienceOn
26 Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004;22:4357-68   DOI   ScienceOn
27 Kitajima K, Murakami K, Yamasaki E, Hagiwara S, Fukasawa I, Inaba N, et al. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer. Ann Nucl Med 2008;22:103-9   DOI   ScienceOn